NO309679B1 - Arylalkyldiazinoner, farmasöytiske preparater og anvendelse av forbindelsene til fremstilling av legemidler - Google Patents
Arylalkyldiazinoner, farmasöytiske preparater og anvendelse av forbindelsene til fremstilling av legemidler Download PDFInfo
- Publication number
- NO309679B1 NO309679B1 NO963852A NO963852A NO309679B1 NO 309679 B1 NO309679 B1 NO 309679B1 NO 963852 A NO963852 A NO 963852A NO 963852 A NO963852 A NO 963852A NO 309679 B1 NO309679 B1 NO 309679B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- acid
- acceptable salts
- physiologically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 67
- 239000003814 drug Substances 0.000 title claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 238000004519 manufacturing process Methods 0.000 title description 6
- 229940079593 drug Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- ZUIQPDPVTCODLP-UHFFFAOYSA-N n-[4-[[3-(3,4-dimethoxyphenyl)-4-ethyl-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)CC(=O)N1CC(C=C1)=CC=C1NC(=O)C1=CC=CN=C1 ZUIQPDPVTCODLP-UHFFFAOYSA-N 0.000 claims 1
- NZUBMTQQNISIDZ-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=CN=C1 NZUBMTQQNISIDZ-UHFFFAOYSA-N 0.000 claims 1
- UZFKGQZERPKMQX-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]pyridine-4-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=NC=C1 UZFKGQZERPKMQX-UHFFFAOYSA-N 0.000 claims 1
- -1 methylenedioxy Chemical group 0.000 abstract description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract description 6
- 125000004076 pyridyl group Chemical group 0.000 abstract description 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 10
- 239000002253 acid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- NASLINFISOTVJJ-UHFFFAOYSA-N 1,2-oxazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CC=NO1 NASLINFISOTVJJ-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- HNIYMECRMVGTPJ-UHFFFAOYSA-N 2-[(4-aminophenyl)methyl]-6-(3,4-dimethoxyphenyl)-4,5-dihydropyridazin-3-one Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC1=CC=C(N)C=C1 HNIYMECRMVGTPJ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- TXJKATOSKLUITR-UHFFFAOYSA-N pyrazine-2-carbonyl chloride Chemical compound ClC(=O)C1=CN=CC=N1 TXJKATOSKLUITR-UHFFFAOYSA-N 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- HMZVEJHYLSVILI-UHFFFAOYSA-N 2-[(3-aminophenyl)methyl]-6-(3,4-dimethoxyphenyl)-4,5-dihydropyridazin-3-one Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC1=CC=CC(N)=C1 HMZVEJHYLSVILI-UHFFFAOYSA-N 0.000 description 1
- PZNRFDHGWUVLFY-UHFFFAOYSA-N 2-[(3-aminophenyl)methyl]-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-4,5-dihydropyridazin-3-one Chemical compound N1=C(C=2C=C(OC3CCCC3)C(OC)=CC=2)C(CC)CC(=O)N1CC1=CC=CC(N)=C1 PZNRFDHGWUVLFY-UHFFFAOYSA-N 0.000 description 1
- QKSFCXULPYSRAK-UHFFFAOYSA-N 2-[(3-aminophenyl)methyl]-6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydropyridazin-3-one Chemical compound C1=C(OC)C(OCC)=CC(C=2CCC(=O)N(CC=3C=C(N)C=CC=3)N=2)=C1 QKSFCXULPYSRAK-UHFFFAOYSA-N 0.000 description 1
- GJCVMDQQJCFDKP-UHFFFAOYSA-N 2-[(4-aminophenyl)methyl]-6-(3-cyclopentyloxy-4-methoxyphenyl)-4,5-dihydropyridazin-3-one Chemical compound COC1=CC=C(C=2CCC(=O)N(CC=3C=CC(N)=CC=3)N=2)C=C1OC1CCCC1 GJCVMDQQJCFDKP-UHFFFAOYSA-N 0.000 description 1
- STOYHSYFGICUND-UHFFFAOYSA-N 2-[(4-aminophenyl)methyl]-6-(3-ethoxy-4-methoxyphenyl)-4,5-dihydropyridazin-3-one Chemical compound C1=C(OC)C(OCC)=CC(C=2CCC(=O)N(CC=3C=CC(N)=CC=3)N=2)=C1 STOYHSYFGICUND-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- MQNJWTBFKHTICB-UHFFFAOYSA-N 3-[(3-aminophenyl)methyl]-5-(3,4-dimethoxyphenyl)-6-ethyl-6h-1,3,4-thiadiazin-2-one Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)SC(=O)N1CC1=CC=CC(N)=C1 MQNJWTBFKHTICB-UHFFFAOYSA-N 0.000 description 1
- RCWFQIICHNGYHS-UHFFFAOYSA-N 3-[(4-aminophenyl)methyl]-5-(3,4-dimethoxyphenyl)-6-ethyl-6h-1,3,4-thiadiazin-2-one Chemical compound N1=C(C=2C=C(OC)C(OC)=CC=2)C(CC)SC(=O)N1CC1=CC=C(N)C=C1 RCWFQIICHNGYHS-UHFFFAOYSA-N 0.000 description 1
- UQBLPIYKRHSTOB-UHFFFAOYSA-N 3-[(4-aminophenyl)methyl]-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-6h-1,3,4-thiadiazin-2-one Chemical compound N1=C(C=2C=C(OC3CCCC3)C(OC)=CC=2)C(CC)SC(=O)N1CC1=CC=C(N)C=C1 UQBLPIYKRHSTOB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IKALLHNQFVFGFY-UHFFFAOYSA-N 4,5-dihydro-1h-pyridazin-6-one;hydrochloride Chemical compound Cl.O=C1CCC=NN1 IKALLHNQFVFGFY-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- OPOLGUQCQBXMKN-UHFFFAOYSA-N 6-ethyl-1,3,4-oxadiazin-2-one Chemical compound CCC1=CN=NC(=O)O1 OPOLGUQCQBXMKN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- PJMGRXXDPFGROQ-UHFFFAOYSA-N Cl.C(C1=CC=NC=C1)(=O)NC1=CC=C(CN2N=C(CCC2=O)C2=CC(=C(C=C2)OC)OCC)C=C1 Chemical compound Cl.C(C1=CC=NC=C1)(=O)NC1=CC=C(CN2N=C(CCC2=O)C2=CC(=C(C=C2)OC)OCC)C=C1 PJMGRXXDPFGROQ-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000012658 Skin autoimmune disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- WFJRIDQGVSJLLH-UHFFFAOYSA-N methyl n-aminocarbamate Chemical compound COC(=O)NN WFJRIDQGVSJLLH-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- MQZDKLBSXVEHCR-UHFFFAOYSA-N n-[3-[[3-(3-ethoxy-4-methoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CCC(=O)N(CC=3C=C(NC(=O)C=4C=NC=CC=4)C=CC=3)N=2)=C1 MQZDKLBSXVEHCR-UHFFFAOYSA-N 0.000 description 1
- ZYQNZHAOXKCSQR-UHFFFAOYSA-N n-[4-[[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=NO1 ZYQNZHAOXKCSQR-UHFFFAOYSA-N 0.000 description 1
- BTUUBDYJMHFGGV-UHFFFAOYSA-N n-[4-[[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]pyrazine-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CN=CC=N1 BTUUBDYJMHFGGV-UHFFFAOYSA-N 0.000 description 1
- HNKIVFWNYCJMMO-UHFFFAOYSA-N n-[4-[[3-(3,4-dimethoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CCC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=CN=C1 HNKIVFWNYCJMMO-UHFFFAOYSA-N 0.000 description 1
- GVNSPPGQBCFJIX-UHFFFAOYSA-N n-[4-[[3-(3-cyclopentyloxy-4-methoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]pyridine-3-carboxamide Chemical compound COC1=CC=C(C=2CCC(=O)N(CC=3C=CC(NC(=O)C=4C=NC=CC=4)=CC=3)N=2)C=C1OC1CCCC1 GVNSPPGQBCFJIX-UHFFFAOYSA-N 0.000 description 1
- ZOYFOSSAHQFOOR-UHFFFAOYSA-N n-[4-[[3-(3-ethoxy-4-methoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CCC(=O)N(CC=3C=CC(NC(=O)C=4ON=CC=4)=CC=3)N=2)=C1 ZOYFOSSAHQFOOR-UHFFFAOYSA-N 0.000 description 1
- RYAZKYJTMOBZAY-UHFFFAOYSA-N n-[4-[[3-(3-ethoxy-4-methoxyphenyl)-6-oxo-4,5-dihydropyridazin-1-yl]methyl]phenyl]pyrazine-2-carboxamide Chemical compound C1=C(OC)C(OCC)=CC(C=2CCC(=O)N(CC=3C=CC(NC(=O)C=4N=CC=NC=4)=CC=3)N=2)=C1 RYAZKYJTMOBZAY-UHFFFAOYSA-N 0.000 description 1
- ZHHHFJJAZZOXIF-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]-1,2-oxazole-5-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=NO1 ZHHHFJJAZZOXIF-UHFFFAOYSA-N 0.000 description 1
- OYVOVVFQUKLKKO-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]pyrazine-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CN=CC=N1 OYVOVVFQUKLKKO-UHFFFAOYSA-N 0.000 description 1
- KGTFSEAAKSGHPC-UHFFFAOYSA-N n-[4-[[5-(3,4-dimethoxyphenyl)-2-oxo-6h-1,3,4-thiadiazin-3-yl]methyl]phenyl]thiophene-2-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CSC1=O)=NN1CC(C=C1)=CC=C1NC(=O)C1=CC=CS1 KGTFSEAAKSGHPC-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/04—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Photoreceptors In Electrophotography (AREA)
- Polymerization Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Saccharide Compounds (AREA)
Description
Oppfinnelsen vedrører arylalkyldiazinonderivater med formel I
hvor
B betyr usubstituert pyrazinyl, 3-pyridyl, 4-pyridyl,
isoksazolyl eller tienyl,
Q mangler eller betyr alkylen med 1-4 C-atomer,
X betyr CH2 eller S,
R<1> og R<2> betyr uavhengig av hverandre H eller A,
R<3> og R<4> betyr uavhengig av hverandre OR<5>,
R<5> betyr A, eller sykloalkyl med 3-7 C-atomer, og
A betyr alkyl med 1-4 C-atomer,
samt deres fysiologisk akseptable salter.
Tiadiazinonderivater er kjent fra f.eks. DE 4134893.
Til grunn for oppfinnelsen lå den oppgave å finne
frem til nye forbindelser med verdifulle egenskaper, særlig slike som kan anvendes til fremstilling av legemidler.
Det ble funnet at forbindelsene med formel I og deres salter har svært verdifulle farmakologiske egenskaper ved god forenlighet.
Særlig utviser de en fosfodiesterase IV-hemming og
kan anvendes til behandling av astmatiske sykdommer. Den anti-astmatiske virkning kan f.eks. bestemmes etter fremgangsmåten til T. Olsson, Acta Allergologica, 26, 438-447 (1971) .
Forbindelsene utviser dessuten en hemmende virkning
på dannelsen av TNF (tumornekrosefaktor) og egner seg således til behandling av allergiske og inflammatoriske sykdommer, autoimmunsykdommer og transplantatavstøtningsreaksjoner. De kan videre anvendes til behandling av hukommelsesforstyrrel-
ser.
Forbindelsene med formel I kan anvendes som aktive legemiddelforbindelser innen human- og veterinærmedisinen. Videre kan de anvendes som mellomprodukter til fremstilling av ytterligere aktive legemiddelforbindelser.
Forbindelsene med formel I samt deres salter kan fremstilles ved en fremgangsmåte hvor en forbindelse med formel II
hvor
R<1>, R2, R3, R4 og X har de angitte betydninger,
omsettes med en forbindelse med formel III
hvor
B og Q har de angitte betydninger, og
L betyr Cl, Br, OH eller en reaksjonsdyktig, forestret
0H-gruppe,
eller
en forbindelse med formel IV
hvor
R<1>, R<2>, R<3>, <R4>, Q og X har de angitte betydninger, omsettes med en forbindelse med formel V
hvor
B har den angitte betydning, og
L betyr Cl, Br, OH eller en reaksjonsdyktig, forestret
OH-gruppe,
og/eller
en basisk forbindelse med formel I overføres ved behandling med en syre til et av dens salter.
Ovenfor og nedenunder har restene R<1>, R<2>, R<3>, R<4>, B, Q og X de for formlene I, II, III, IV og V angitte betydninger såfremt ikke noe annet er uttrykkelig angitt.
I formlene ovenfor er alkyl fortrinnsvis uforgrenet og betyr fortrinnsvis metyl, etyl eller propyl.
Sykloalkyl har 3-7 C-atomer og står foretrukket for syklopropyl og syklobutyl.
Alkylen er fortrinnsvis uforgrenet og betyr foretrukket metylen eller etylen.
Av restene R<1> og R2 står én fortrinnsvis for H, mens den andre foretrukket betyr propyl eller butyl, særlig foretrukket imidlertid etyl eller metyl. Videre betyr hver av R<1> og R<2> også foretrukket hydrogen.
Restene R<3> og R4 kan være like eller forskjellige og står i 3- eller 4-stillingen i fenylringen. Særlig foretrukket står de hver for metoksy, etoksy, propoksy eller syklopentok-sy.
For hele oppfinnelsen gjelder det at samtlige rester som opptrer flere ganger, kan være like eller forskjellige, dvs. er uavhengige av hverandre.
Oppfinnelsens gjenstand er således særlig slike forbindelser med formel I hvor minst én av de nevnte rester har en av de ovenfor angitte, foretrukne betydninger. Noen foretrukne grupper av forbindelser kan uttrykkes gjennom de følgende delformler Ia-Id, som tilsvarer formel I, og hvor de ikke nærmere angitte rester har de for formel I angitte betydninger, hvor imidlertid:
i Ia R<1> betyr H,
R<2> betyr H eller A,
R<3> betyr OA, og
X betyr S;
i Ib R<1> betyr H,
R<2> betyr metyl eller etyl,
R3 og R<4> betyr uavhengig av hverandre OA, og X betyr S;
i Ic R<1> betyr H,
R<2> betyr metyl eller etyl,
R3 og R<4> betyr uavhengig av hverandre OR<5>, og B betyr en pyridylrest;
i Id R<1> og R<2> betyr H,
R3 og R<4> betyr uavhengig av hverandre OA,
B betyr en pyridylrest, og
X betyr S eller CH2.
Forbindelsene med formel I og også utgangsforbindelsene for deres fremstilling fremstilles for øvrig etter i og for seg kjente fremgangsmåter, slik som de er blitt beskrevet i litteraturen (f.eks. i standardverkene som Houben-Weyl, Methoden der organischen Chemie, Georg-Thieme-Verlag, Stutt-gart; særlig imidlertid i DE 19502699.3), og da under reaksjonsbetingelser som er kjent og egnet for de nevnte om-setninger. Man kan da også gjøre bruk av i og for seg kjente, her ikke nærmere belyste varianter.
I forbindelsene med formlene II og IV har R<1>, R<2>, R3 og R<4> de angitte betydninger, særlig de angitte, foretrukne betydninger.
I forbindelsene med formlene III og V står Q fortrinnsvis for metylen eller etylen.
B har i forbindelsene med formlene III og V de angitte betydninger, mens L betyr Cl, Br, OH eller en reaksjonsdyktig, forestret OH-gruppe.
Dersom L betyr en reaksjonsdyktig, forestret OH-gruppe, så er denne fortrinnsvis alkylsulfonyloksy med 1-6 C-atomer (foretrukket metylsulfonyloksy) eller arylsulfonyloksy med 6-10 C-atomer (foretrukket fenyl- eller p-tolylsulfonyl-oksy, videre også 2-naftalensulfonyloksy).
Utgangsforbindelsene kan, om ønsket, også dannes in situ, slik at man ikke isolerer dem fra reaksjonsblandingen, men straks omsetter dem videre til forbindelsene med formel I. På den annen side er det mulig å gjennomføre reaksjonen trinn-vis .
Forbindelsene med formel I kan fortrinnsvis fås ved at man omsetter forbindelser med formel II med forbindelser med formel III.
Utgangsforbindelsene med formlene II og III er delvis kjent. Såfremt de ikke er kjent, kan de fremstilles etter i og for seg kjente fremgangsmåter.
Pyridazinoner med formel II er beskrevet f.eks. i Eur. J. Med. Chem.-Chim. Therapeut., 9, 644-650 (1977).
Tiadiazinoner med formel II og deres fremstilling er beskrevet f.eks. i den tyske patentsøknad P 4134893.
6-etyl-l,3,4-oksadiazin-2-on med formel II kan fås f.eks. ved å gå ut fra butyroveratron, ved bromering over a-brombutyroveratron, utbytting av Br-atomet med en OH-gruppe ved hjelp av kaliumformiat i metanol, påfølgende omsetning med karbometoksyhydrazin til det tilsvarende hydrazonderivat og ringslutning ved hjelp av kaliumkarbonat i toluen.
Omsetningen av forbindelsene med formel II med forbindelsene med formel III skjer særlig i nærvær eller fravær av et inert oppløsningsmiddel ved temperaturer mellom ca. -20 og ca. 150 °C, fortrinnsvis mellom 20 og 100 °C.
Som inert oppløsningsmiddel egner seg f.eks. hydrokarboner som heksan, petroleter, benzen, toluen eller xylen; klorerte hydrokarboner som trikloretylen, 1,2-dikloretan, karbontetraklorid, kloroform eller diklormetan; alkoholer som metanol, etanol, isopropanol, n-propanol, n-butanol eller tert.-butanol; etere som dietyleter, diisopropyleter, tetra-hydrofuran (THF) eller dioksan; glykoletere som etylenglykol-monometyl- eller -monoetyleter (metylglykol eller etylglykol), etylenglykoldimetyleter (diglym); ketoner som aceton eller butanon; amider som acetamid, dimetylacetamid eller dimetyl-formamid (DMF); nitriler som acetonitril; sulfoksider som dimetylsulfoksid (DMSO); karbondisulfid; karboksylsyrer som maursyre eller eddiksyre; nitroforbindelser som nitrometan eller nitrobenzen; estere som etylacetat; eller blandinger av de nevnte oppløsningsmidler.
Forbindelser med formel I kan dessuten fås ved at man omsetter forbindelser med formel IV med forbindelser med formel V. Utgangsforbindelsene med formlene IV og V er som regel kjent. Dersom de ikke er kjent, kan de fremstilles etter i og for seg kjente fremgangsmåter. Forbindelser med formel IV er særlig kjent fra DE 19502699 og DE 19514568.
I forbindelsene med formel V betyr resten -CO-L en foraktivert karboksylsyre, fortrinnsvis et karboksylsyrehalo-genid.
Omsetningen av forbindelsene med formel IV med forbindelser med formel V skjer under de samme betingelsene med hensyn til reaksjonstid, temperatur og oppløsningsmiddel som er beskrevet for omsetningen av forbindelser med formel II med forbindelser med formel III.
En base med formel I kan overføres med en syre til det tilhørende syreaddisjonssalt, f.eks. ved omsetning av ekvivalente mengder av basen og syren i et inert oppløsnings-middel som etanol, og påfølgende inndamping. For denne omsetningen kommer det særlig på tale med syrer som gir fysiologisk akseptable salter. Således kan det anvendes uorganiske syrer, f.eks. svovelsyre, salpetersyre, hydrogenhalogensyrer som saltsyre eller hydrogenbromsyre, fosforsyrer som ortofosfor-syre, sulfaminsyre, videre organiske syrer, særlig alifatiske, alisykliske, aralifatiske, aromatiske eller heterosykliske en-eller flerbasiske karboksyl-, sulfon- eller svovelsyrer, f.eks. maursyre, eddiksyre, propionsyre, pivalinsyre, dietyl-eddiksyre, malonsyre, ravsyre, pimelinsyre, fumarsyre, malein-syre, melkesyre, vinsyre, eplesyre, sitronsyre, glukonsyre, askorbinsyre, nikotinsyre, isonikotinsyre, metan- eller etan-sulfonsyre, etandisulfonsyre, 2-hydroksyetansulfonsyre, benzensulfonsyre, p-toluensulfonsyre, naftalenmono- og -di-sulfonsyrer, og laurylsvovelsyre. Salter med fysiologisk ikke akseptable syrer, f.eks. pikrater, kan anvendes til isolering og/eller rensing av forbindelsene med formel I.
På den annen side kan, om ønsket, de frie basene med formel I frisettes fra sine salter med baser (f.eks. natrium-eller kaliumhydroksid eller -karbonat).
Forbindelser med formel I kan inneholde ett eller flere asymmetrisentre. I dette tilfellet foreligger de vanlig-vis i racemisk form. Erholdte racemater kan oppløses mekanisk eller kjemisk i sine enantiomerer etter i og for seg kjente fremgangsmåter. Fortrinnsvis dannes diastereomerer fra den racemiske blanding ved omsetning med et optisk aktivt oppløs-ningsmiddel .
Naturligvis er det mulig å erholde optisk aktive forbindelser med formel I etter de ovenfor beskrevne fremgangsmåter, idet man anvender utgangsforbindelser som allerede er optisk aktive.
Formel I omfatter alle stereoisomerer og deres blandinger, f.eks. racematet.
Gjenstand for oppfinnelsen er videre anvendelsen av forbindelsene med formel I og/eller deres fysiologisk akseptable salter til fremstilling av farmasøytiske preparater, særlig på ikke-kjemisk måte. Herved kan de sammen med minst ett fast, flytende og/eller halvflytende bærer- eller hjelpe-stoff, og eventuelt i kombinasjon med én eller flere ytterligere aktive forbindelser, bringes i en egnet doseringsform.
Gjenstand for oppfinnelsen er også forbindelser med formel I og deres fysiologisk akseptable salter som fosfodiesterase IV-hemmere.
Gjenstand for oppfinnelsen er dessuten forbindelser med formel I og deres fysiologisk akseptable salter for bekjempelse av astma, allergier og betennelsessykdommer, autoimmunsykdommer og transplantatavstøtningsreaksjoner.
Gjenstand for oppfinnelsen er videre farmasøytiske preparater som inneholder minst én forbindelse med formel I og/eller et av dens fysiologisk akseptable salter.
Disse preparatene kan anvendes som legemidler innen human- eller veterinærmedisinen. Som bærerstoffer kommer det på tale med organiske eller uorganiske stoffer som egner seg for enteral (f.eks. oral), parenteral eller topisk applika-sjon, og som ikke reagerer med de nye forbindelsene, f.eks. vann, planteoljer, benzylalkoholer, alkylenglykoler, poly-etylenglykoler, glyseroltriacetat, gelatin, karbohydrater som laktose eller stivelse, magnesiumstearat, talkum eller vaselin. Til oral anvendelse tjener særlig tabletter, piller, drasjeer, kapsler, pulvere, granulater, siruper, safter eller dråper, til rektal anvendelse suppositorier, til parenteral anvendelse oppløsninger, fortrinnsvis olje- eller vannoppløs-ninger, videre suspensjoner, emulsjoner eller implantater, og for topisk anvendelse salver, kremer eller pudder. De nye forbindelsene kan også lyofiliseres og de erholdte lyofilisater anvendes f.eks. til fremstilling av injeksjonspreparater. De angitte preparater kan være sterilisert og/eller inneholde hjelpestoffer som glide-, konserverings-, stabiliserings-og/eller fuktemiddel, emulgatorer, salter for påvirkning av det osmotiske trykk, bufferstoffer, farge-, smaks- og/eller flere ytterligere aktive forbindelser, f.eks. ett eller flere vitaminer.
Forbindelsene med formel I og deres fysiologisk akseptable salter kan anvendes ved bekjempelsen av sykdommer hvor en forhøyelse av cAMP-speilet (sykloadenosinmonofosfat-speilet) fører til betennelseshemming eller -forhindring og muskelavspenning. Forbindelsene ifølge oppfinnelsen kan særlig finne anvendelse ved behandlingen av allergier, astma, kronisk bronkitt, atopisk dermatitt, psoriasis og andre hudsykdommer og autoimmunsykdommer.
FARMAKOLOGISK RAPPORT
De følgende IC50-verdier (konsentrasjoner i mol/liter, dvs. 50 % inhibering av fosfodiesterase IV) ble oppnådd for noen karakteristiske forbindelser med formel
I.
Litteratur:
1. P.J. Knight og J.A. Trinick, Preparation of Myofibrils, Methods in Enzymology, 85:9 (1982) 2. M. Klockow og R. Jonas, Particulate cAMP-specific phosphodiesterase (P-PDE) in cardiac ventricle of guinea pig, Nauyn.-Schmiedeberg's Arch Pharmacol., 339:209 (1989) 3. W.J. Thompson et al., Advances in cyclic Nucleotide Research, vol. 10, Raven Press, New York, 69 (1979)
Ovenfor og nedenunder er alle temperaturer angitt i °C. I de etterfølgende eksempler betyr "vanlig opparbeidelse": Om nødvendig tilsettes vann, om nødvendig innstilles, alt etter sluttproduktets konstitusjon, på pH-verdi mellom 2 og 10, det ekstraheres med etylacetat eller diklormetan, sepa-reres, den organiske fase tørkes over natriumsulfat, inndampes og renses ved kromatografi på silikagel og/eller ved krystal-lisasjon.
Eksempel
En oppløsning av 3,4 g 2-(4-aminobenzyl)-6-(3,4-di-metoksyfenyl)-2,3,4,5-tetrahydropyridazin-3-on, smp. 184 °C, og 0,75 ml pyridin i 100 ml diklormetan tilsettes 1,4 g nikotinoylklorid, og det omrøres i 1 time. Oppløsningsmidlet fjernes, og det opparbeides på vanlig måte. Etter omkrystal-lisasjon får man 2-(4-nikotinoylaminobenzyl)-6-(3,4-dimetoksy-fenyl)-2 , 3,4,5-tetrahydropyridazin-3-on. (Referansefremstil-ling).
Analogt kan de følgende "aminderivater" anvendes: 2-(3-aminobenzyl)-6-(3,4-dimetoksyfenyl)-2,3,4,5-tetrahydropyridazin-3-on, smp. 14 0 °C, 2- (3-aminobenzyl)-6-(3-syklopentyloksy-4-metoksy-fenyl)-5-etyl-2,3,4,5-tetrahydropyridazin-3-on, smp. 109 °C, 3 -(4 -aminobenzyl)-5-(3,4-dimetoksyfenyl)-6-etyl-3,6-dihydro-l,3,4-tiadiazin-2-on, smp. 105 °C, 3 -(3 -aminobenzyl)-5-(3,4-dimetoksyfenyl)-6-etyl-3,6-dihydro-1,3,4-tiadiazin-2-on, smp. 112 °C, og
3- (4-aminobenzyl)-5-(3-syklopentyloksy-4-metoksy-fenyl)-6-etyl-3,6-dihydro-l,3,4-tiadiazin-2-on, smp. 132 °C.
Analogt får man ved omsetning av det tilsvarende "aminderivat" med tiofen-2-karboksylsyreklorid den følgende forbindelse: 3-(4-(tiofen-2-karbonylamino)-benzyl)-5-(3,4-di-metoksyf enyl) -3,6-dihydro-l,3,4-tiadiazin-2-on, smp. 186 °C.
Analogt får man ved omsetning av de tilsvarende "aminderivater" med pyrazin-2-karboksylsyreklorid de følgende forbindelser: 2- (4-pyrazinkarbonylaminobenzyl)-6-(3,4-dimetoksy-fenyl)-2,3,4,5-tetrahydropyridazin-3-on, smp. 197 °C, og
3- (4-pyrazinkarbonylaminobenzyl)-5-(3,4-dimetoksy-fenyl)-3,6-dihydro-l,3,4-tiadiazin-2-on, smp. 202 °C.
Analogt får man ved omsetning av de tilsvarende "aminderivater" med isoksazol-5-karboksylsyreklorid de følgende forbindelser: 2- (4-(isoksazol-5-karbonylamino)-benzyl)-6-(3,4-di-metoksyf enyl) -2 , 3 , 4 , 5-tetrahydropyridazin-3 -on, smp. 217 °C, og
3- (4-(isoksazol-5-karbonylamino)-benzyl)-5-(3,4-di-metoksyf enyl) -3 , 6-dihydro-l, 3 , 4-tiadiazin-2-on, smp. 196 °C.
Analogt får man ved omsetning
av 2-(3-aminobenzyl)-6-(3-etoksy-4-metoksyfenyl)-2 , 3,4,5-tetrahydropyridazin-3-on med nikotinoylklorid:
2-(3-nikotinoylaminobenzyl)-6-(3-etoksy-4-metoksy-fenyl)-2,3,4,5-tetrahydropyridazin-3-on, smp. 204 °C, av 2-(4-aminobenzyl)-6-(3-etoksy-4-metoksyfenyl)-2,3,4,5-tetrahydropyridazin-3-on med isonikotinoylklorid: 2-(4-isonikotinoylaminobenzyl)-6-(3-etoksy-4-metoksy-fenyl)-2,3,4,5-tetrahydropyridazin-3-on-hydroklorid, smp. 252 °C, med pyrazin-2-karboksylsyreklorid: 2-(4-pyrazinkarbonylaminobenzyl)-6-(3-etoksy-4-metoksyfenyl)-2,3,4,5-tetrahydropyridazin-3-on, smp. 202 °C, med isoksazol-5-karboksylsyreklorid: 2-(4-(isoksazol-5-karbonylamino)-benzyl)-6-(3-etoksy-4-metoksyfenyl)-2,3,4,5-tetrahydropyridazin-3-on, smp. 192 °C, av 2 -(4 -aminobenzyl)-6-(3 -syklopentyloksy-4-metoksy-fenyl)-2,3,4,5-tetrahydropyridazin-3-on med nikotinoylklorid: 2-(4-nikotinoylaminobenzyl)-6-(3-syklopentyloksy-4-metoksyfenyl)-2,3,4,5-tetrahydropyridazin-3-on, smp. 205 °C, og av 2 -(4-aminobenzyl)-6-(3,4-dimetoksyfenyl)-2,3,4,5-tetrahydropyridazin-3-on med nikotinoylklorid: 2-(4-nikotinoylaminobenzyl)-6-(3,4-dimetoksyfenyl)-
2,3,4,5-tetrahydropyridazin-3-on-hydroklorid, smp. 212 °C.
De etterfølgende eksempler vedrører farmasøytiske preparater.
Eksempel A
Inj eksi onsglass
En oppløsning av 10 0 g av en aktiv forbindelse med formel I og 5 g dinatriumhydrogenfosfat i 3 1 dobbeltdestillert vann innstilles på pH 6,5 med 2 N saltsyre, steril-f Utreres, fylles i inj eks j onsglass, lyofiliseres under sterile betingelser og lukkes sterilt. Hvert injeksjonsglass inneholder 5 mg aktiv forbindelse.
Eksempel B
Suppositorier
En blanding av 20 g av en aktiv forbindelse med formel I med 100 g soyalecitin og 1400 g kakaosmør smeltes, helles i former og får avkjøles. Hvert suppositorium inneholder 20 mg aktiv forbindelse.
Eksempel C
Oppløsning
Det lages en oppløsning av 1 g av en aktiv forbindelse med formel I, 9,3 8 g NaH2P04-2 H20, 2 8,48 g Na2HP04- 12 H20 og 0,1 g benzalkoniumklorid i 940 ml dobbeltdestillert vann. Det innstilles på pH 6,8, fylles opp til 1 1 og steriliseres ved bestråling. Denne oppløsningen kan anvendes i form av øyedrå-per .
Eksempel D
Salve
500 mg av en aktiv forbindelse med formel I blandes med 99,5 g vaselin under aseptiske betingelser.
Eksempel E
Tabletter
En blanding av 1 kg aktiv forbindelse med formel I, 4 kg laktose, 1,2 kg potetstivelse, 0,2 kg talkum og 0,1 kg magnesiumstearat presses på vanlig måte til tabletter, slik at hver tablett inneholder 10 mg aktiv forbindelse.
Eksempel F
Drasjeer
Analogt med eksempel E presses tabletter som deretter belegges med et belegg av sakkarose, potetstivelse, talkum, tragant og fargestoff.
Eksempel G
Kapsler
2 kg aktiv forbindelse med formel I fylles på vanlig måte i hardgelatinkapsler, slik at hver kapsel inneholder
20 mg av den aktive forbindelse.
Eksempel H
Ampuller
En oppløsning av 1 kg aktiv forbindelse med formel I i 60 1 dobbeltdestillert vann sterilfiltreres, fylles i ampuller, lyofiliseres under sterile betingelser og lukkes sterilt. Hver ampulle inneholder 10 mg aktiv forbindelse.
Eksempel I
Inhalas i ons spray
14 g aktiv forbindelse med formel I oppløses i 10 1 isoton NaCl-oppløsning, og oppløsningen fylles i kommersielt tilgjengelige sprøytebeholdere med pumpemekanisme. Oppløs-ningen kan sprøytes inn i munn eller nese. Et sprøytestøt (ca. 0,1 ml) tilsvarer en dose på ca. 0,14 mg.
Claims (6)
1. Forbindelser,
karakterisert ved at de har formel I
hvor
B betyr usubstituert pyrazinyl, 3-pyridyl, 4-pyridyl,
isoksazolyl eller tienyl,
Q mangler eller betyr alkylen med 1-4 C-atomer,
X betyr CH2 eller S,
R<1> og R<2> betyr uavhengig av hverandre H eller A,
R3 og R<4> betyr uavhengig av hverandre OR<5>,
R<5> betyr A, eller sykloalkyl med 3-7 C-atomer, og A betyr alkyl med 1-4 C-atomer,
samt deres fysiologisk akseptable salter.
2. Forbindelse I ifølge krav 1, karakterisert ved at den er (a) 3-(4-nikotinoylaminobenzyl)-5-(3,4-dimetoksyfenyl)-3,6-dihydro-l,3,4-tiadiazin-2-on, (b) 3-(4-isonikotinoylaminobenzyl)-5-(3,4-dimetoksy-fenyl)-3,6-dihydro-l,3,4-tiadiazin-2-on eller (c) 2-(4-nikotinoylaminobenzyl)-6-(3,4-dimetoksyfenyl)-5-etyl-2,3,4,5-tetrahydropyridazin-3-on.
3. Farmasøytisk preparat,
karakterisert ved et innhold av minst én forbindelse med formel I ifølge krav 1, og/eller et av dens fysiologisk akseptable salter.
4. Forbindelser for bekjempelse av astma, allergier og betenneIsessykdommer, autoimmunsykdommer og transplantatav-støtningsreaksj oner,
karakterisert ved at de har formel I ifølge krav 1, samt deres fysiologisk akseptable salter.
5. Forbindelser for anvendelse som fosfodiesterase IV-hemmere,
karakterisert ved at de har formel I ifølge krav 1, samt deres fysiologisk akseptable salter.
6. Anvendelse av forbindelser med formel I ifølge krav 1 og/eller deres fysiologisk akseptable salter til fremstilling av et legemiddel for anvendelse ved astma, allergier og beten-nelses sykdommer , autoimmunsykdommer og transplantatavstøt-ningsreaksjoner, samt hukommelsesforstyrrelser.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19533975A DE19533975A1 (de) | 1995-09-14 | 1995-09-14 | Arylalkyl-diazinone |
Publications (3)
Publication Number | Publication Date |
---|---|
NO963852D0 NO963852D0 (no) | 1996-09-13 |
NO963852L NO963852L (no) | 1997-03-17 |
NO309679B1 true NO309679B1 (no) | 2001-03-12 |
Family
ID=7772083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO963852A NO309679B1 (no) | 1995-09-14 | 1996-09-13 | Arylalkyldiazinoner, farmasöytiske preparater og anvendelse av forbindelsene til fremstilling av legemidler |
Country Status (24)
Country | Link |
---|---|
US (1) | US5859008A (no) |
EP (1) | EP0763534B1 (no) |
JP (1) | JP4149532B2 (no) |
KR (1) | KR970015578A (no) |
CN (1) | CN1110495C (no) |
AT (1) | ATE233258T1 (no) |
AU (1) | AU716113B2 (no) |
BR (1) | BR9603736A (no) |
CA (1) | CA2185397C (no) |
CZ (1) | CZ286567B6 (no) |
DE (2) | DE19533975A1 (no) |
DK (1) | DK0763534T3 (no) |
ES (1) | ES2192213T3 (no) |
HU (1) | HUP9602511A3 (no) |
MX (1) | MX9604020A (no) |
NO (1) | NO309679B1 (no) |
PL (1) | PL185961B1 (no) |
PT (1) | PT763534E (no) |
RU (1) | RU2167159C2 (no) |
SI (1) | SI0763534T1 (no) |
SK (1) | SK281474B6 (no) |
TW (1) | TW363063B (no) |
UA (1) | UA48946C2 (no) |
ZA (1) | ZA967766B (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19502699A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | Arylalkyl-thiadiazinone |
JP2002508368A (ja) * | 1997-12-15 | 2002-03-19 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | ジヒドロベンゾフラン |
SI1070056T1 (en) * | 1998-03-14 | 2004-12-31 | Altana Pharma Ag | Phthalazinone pde iii/iv inhibitors |
CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
TR200201128T2 (tr) | 1999-10-25 | 2002-08-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. |
AU781503B2 (en) | 1999-10-25 | 2005-05-26 | Altana Pharma Ag | Phthalazinone derivatives as PDE 4 inhibitors |
WO2001094319A1 (en) | 2000-06-05 | 2001-12-13 | Altana Pharma Ag | Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors |
DE10064997A1 (de) * | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
WO2002072103A1 (en) * | 2001-02-12 | 2002-09-19 | Merck Patent Gmbh | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
CZ20032491A3 (cs) | 2001-02-15 | 2004-01-14 | Altana Pharma Ag | Ftalazinonpiperidinové deriváty |
PL363544A1 (en) | 2001-04-25 | 2004-11-29 | Altana Pharma Ag | Piperazino-derivatives and their use as pde4 inhibitor |
EA200301100A1 (ru) | 2001-04-25 | 2004-06-24 | Алтана Фарма Аг | Новые фталазиноны |
BR0211209A (pt) * | 2001-07-18 | 2004-07-13 | Merck Patent Gmbh | Derivados de 4-(benzilidenoamino)-3-(metilsulfanil)-4h-1,2,4-triazin- 5-ona tendo uma ação antagonìstica de tnf e inibição de pde iv para o tratamento de doenças cardìacas e alergias |
DE10150517A1 (de) * | 2001-10-12 | 2003-04-17 | Merck Patent Gmbh | Verwendung von Phosphodiesterase IV-Inhibitoren |
EP1463509A1 (en) * | 2001-10-31 | 2004-10-06 | MERCK PATENT GmbH | Type 4 phosphodiesterase inhibitors and uses thereof |
ES2195785B1 (es) * | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
DE10227269A1 (de) * | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
MXPA05001354A (es) | 2002-08-10 | 2005-04-28 | Altana Pharma Ag | Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4. |
PL373146A1 (en) * | 2002-08-10 | 2005-08-22 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
AU2004226353A1 (en) | 2003-04-01 | 2004-10-14 | Laboratoires Serono Sa | Inhibitors of phosphodiesterases in infertility |
EP1716123A1 (en) * | 2004-02-04 | 2006-11-02 | Altana Pharma AG | Pyridazinone derivatives and their use as pde4 inhibitors |
JP4778449B2 (ja) | 2004-02-04 | 2011-09-21 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pde4インヒビターとしての2−(ピペリジン−4−イル)−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体 |
ES2251866B1 (es) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251867B1 (es) * | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
DE102005055354A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine |
DE102005055355A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
AU2017232906B2 (en) | 2016-03-16 | 2022-03-31 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector T cell function |
SG11202012464WA (en) | 2018-07-11 | 2021-01-28 | H Lee Moffitt Cancer Center And Research Institute Inc | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE788476A (fr) * | 1971-09-08 | 1973-03-06 | Sandoz Sa | Nouveaux derives de la pyridazinone, leur preparation et leur application comme medicaments |
DE3505609A1 (de) * | 1985-02-19 | 1986-08-21 | Merck Patent Gmbh, 6100 Darmstadt | Benzimidazolyl-pyridazinone |
AU614965B2 (en) * | 1987-06-06 | 1991-09-19 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thiadiazinones |
DE3734083A1 (de) * | 1987-10-08 | 1989-04-20 | Heumann Pharma Gmbh & Co | Benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
GB8816944D0 (en) * | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
US5247076A (en) * | 1991-09-09 | 1993-09-21 | Merck & Co., Inc. | Imidazolidyl macrolides having immunosuppressive activity |
DE4134893A1 (de) * | 1991-10-23 | 1993-04-29 | Merck Patent Gmbh | Thiadiazinone |
DE4310699A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Thiadiazinone |
DE4330915C1 (de) * | 1993-09-11 | 1994-09-08 | Steinel Bernhard Werkzeugmasch | Palettenwechsler für Werkzeugmaschinen |
DE19500558A1 (de) * | 1995-01-11 | 1996-07-18 | Merck Patent Gmbh | 3-Alkoxycarbonyl-thiadiazinone |
DE19502699A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | Arylalkyl-thiadiazinone |
DE19514568A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Arylalkyl-pyridazinone |
-
1995
- 1995-09-14 DE DE19533975A patent/DE19533975A1/de not_active Withdrawn
-
1996
- 1996-08-05 TW TW085109458A patent/TW363063B/zh active
- 1996-08-26 SK SK1100-96A patent/SK281474B6/sk unknown
- 1996-09-05 EP EP96114211A patent/EP0763534B1/de not_active Expired - Lifetime
- 1996-09-05 SI SI9630598T patent/SI0763534T1/xx unknown
- 1996-09-05 ES ES96114211T patent/ES2192213T3/es not_active Expired - Lifetime
- 1996-09-05 AT AT96114211T patent/ATE233258T1/de not_active IP Right Cessation
- 1996-09-05 DK DK96114211T patent/DK0763534T3/da active
- 1996-09-05 PT PT96114211T patent/PT763534E/pt unknown
- 1996-09-05 DE DE59610164T patent/DE59610164D1/de not_active Expired - Lifetime
- 1996-09-09 CZ CZ19962630A patent/CZ286567B6/cs not_active IP Right Cessation
- 1996-09-09 AU AU65517/96A patent/AU716113B2/en not_active Ceased
- 1996-09-11 RU RU96118917/04A patent/RU2167159C2/ru not_active IP Right Cessation
- 1996-09-11 MX MX9604020A patent/MX9604020A/es not_active IP Right Cessation
- 1996-09-12 CN CN96112589A patent/CN1110495C/zh not_active Expired - Fee Related
- 1996-09-12 BR BR9603736A patent/BR9603736A/pt not_active Application Discontinuation
- 1996-09-12 CA CA002185397A patent/CA2185397C/en not_active Expired - Fee Related
- 1996-09-13 KR KR1019960039769A patent/KR970015578A/ko not_active IP Right Cessation
- 1996-09-13 UA UA96093557A patent/UA48946C2/uk unknown
- 1996-09-13 NO NO963852A patent/NO309679B1/no not_active IP Right Cessation
- 1996-09-13 ZA ZA967766A patent/ZA967766B/xx unknown
- 1996-09-13 PL PL96316070A patent/PL185961B1/pl unknown
- 1996-09-13 HU HU9602511A patent/HUP9602511A3/hu unknown
- 1996-09-13 US US08/714,796 patent/US5859008A/en not_active Expired - Lifetime
- 1996-09-13 JP JP26372796A patent/JP4149532B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO309679B1 (no) | Arylalkyldiazinoner, farmasöytiske preparater og anvendelse av forbindelsene til fremstilling av legemidler | |
NO312295B1 (no) | Arylalkanoylpyridaziner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstillingderav, samt anvendelse av forbindelsene til fremstilling avpreparatene | |
CA2672521C (en) | Pyrazole derivatives as protein kinase inhibitors | |
WO2006085685A1 (ja) | ピラゾール化合物 | |
SK118494A3 (en) | Piperidine derivatives, method on their production, pharmaceutical agents on their base and method of their production, and using of these derivatives for production of treatments | |
SK283870B6 (sk) | 2-[5-(4-Fluórfenyl)-3-pyridylmetylaminometyl]chróman, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje | |
NO317888B1 (no) | Arylalkanoylpyridaziner, fremgangsmate for fremstilling av forbindelsene, forbindelsene foranvendelse som legemidler, farmasoytiske preparater som inneholder dem, fremgangsmatefor fremstilling av preparatene, samt anvendelse av forbindelsene til fremstilling av legemidler | |
WO1997019078A1 (en) | Pyrido[2, 3-d] pyrimidine derivatives and medicinal compositions thereof | |
CA3175429A1 (en) | Gpr52 modulator compounds | |
JP4740116B2 (ja) | 精神疾患および神経障害の処置のための5−ht受容体アンタゴニスト | |
AU759328B2 (en) | Benzoylpyridazines | |
AU2022202463A1 (en) | Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof | |
DE19604388A1 (de) | Arylalkyl-diazinone | |
NO313415B1 (no) | Oksazolidiner, fremgangsmåte for fremstilling derav, farmasöytiske preparater, fremgangsmåte for fremstilling derav,forbindelsene 5-HT2A-antagonister, samt anvendelse avforbindelsene til fremstilling av legemidler | |
AU2004218161B2 (en) | Benzofuran derivative | |
US6107295A (en) | Arylalkanoyl pyridazines | |
WO2001032173A1 (fr) | Inhibiteurs de neurocytotoxicite de l'acide kainique | |
WO2000009488A1 (fr) | Derives de pyridazinone | |
KR101586714B1 (ko) | 피라졸 화합물 | |
MXPA01010034A (es) | Uso de arilalcanoilpiridazinas. | |
TWI643847B (zh) | Novel benzoazepine derivatives and their medical uses | |
Branigan | Darmstadt, all of Germany | |
KR20230051939A (ko) | 신규한 캡시드 조립 저해제 | |
MXPA99003479A (en) | New heterocyclylmethyl-substituted pyrazol derivates | |
MXPA00012592A (en) | Aryl alkanoylpyridazines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |